Provided by Tiger Trade Technology Pte. Ltd.

InspireMD

0.7899
+0.01001.28%
Post-market: 0.78990.00000.00%19:30 EDT
Volume:31.98K
Turnover:25.01K
Market Cap:36.72M
PE:-1.22
High:0.8099
Open:0.8000
Low:0.7652
Close:0.7799
52wk High:2.57
52wk Low:0.6300
Shares:46.49M
Float Shares:25.94M
Volume Ratio:0.73
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6464
EPS(LYR):-0.7584
ROE:-202.81%
ROA:-85.85%
PB:1.17
PE(LYR):-1.04

Loading ...

InspireMD Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

InspireMD Q1 revenue jumps 122%, beats estimates on product demand

Reuters
·
May 05

InspireMD Q1 FY26 net loss narrows to $13.7 million; revenue more than doubles to $3.4 million

Reuters
·
May 05

InspireMD Q1 EPS $(0.16) Beats $(0.19) Estimate, Sales $3.398M Beat $2.698M Estimate

Benzinga Earnings
·
May 05

InspireMD Inc - on Track for FDA Approval of Cguard Prime 80 Cm for Tcar in H2 2026

THOMSON REUTERS
·
May 05

InspireMD price target lowered to $4 from $5 at Lake Street

TIPRANKS
·
May 04

InspireMD initiates voluntary U.S. recall of CGuard Prime 135 cm system

TIPRANKS
·
May 04

Piper Sandler Remains a Buy on InspireMD (NSPR)

TIPRANKS
·
May 04

InspireMD Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
May 02

InspireMD Recalls CGuard Prime Delivery System, Pauses U.S. Launch

TIPRANKS
·
May 02

InspireMD Withdraws Guidance, Recalls CGuard Prime

Dow Jones
·
May 02

InspireMD announces FDA approval of IDE application for CGUARDIANS III study

TIPRANKS
·
May 02

InspireMD Inc - Withdraws Prior Full Year 2026 Revenue Guidance

THOMSON REUTERS
·
May 02

InspireMD Inc - Recall Follows Technical Performance of Cguard Prime 135 Cm Not Meeting Expectations

THOMSON REUTERS
·
May 02

InspireMD Inc - FDA Approval, U.S. Availability of Original Cguard Delivery System Anticipated in Q3 2026

THOMSON REUTERS
·
May 02

InspireMD Inc - Recall Does Not Include Cguard Stent Implant

THOMSON REUTERS
·
May 02

InspireMD Announces FDA Approval of Investigational Device Exemption Application for Cguardians Iii Pivotal Study of the Switchguard Neuro Protection System

THOMSON REUTERS
·
May 02

InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

GlobeNewswire
·
May 02

InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System

GlobeNewswire
·
May 02

InspireMD to report Q1 results, host conference call and webcast

Reuters
·
Apr 28